Gustavo Cancela e Penna Alterações moleculares na tumorigênese ...

Liu M, Gelmann E. P53 gene mutations: case study of a clinical marker for solid
tumors. Semin Oncol 2002; 29: 246-257
Louise V, Richards R. Common chromosomal fragile sites and cancer: Focus
on FRAD16D. Cancer Letters 2006; 232: 37-47
Ludes-Meyers J, Bednarek A, Popescu N, Bedford M, Aldaz C. WWOX, the
common chromosomal fragile site, FRAD 16D, cancer gene, Cytogenet
Genome Res 2003; 100: 101-110
Lupi C, Gianini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R,
Santoro M, Miccoli P, Basolo F. Association of BRAFV600E mutation
with poor clinicopathological outcomes in 500 consecutive cases of
papillary thyroid carcinoma. J Clin Encorinol Metab 2007; 92: 4085-4090
Maciel R, Kimura E, Cerutti J. Patogênese dos tumores diferenciados da
tireóide (papilífero e folicular). Arq Bras Endocrinol Metabol 2005; 49:
691-700
McIver B, Grebe S, Wang L, Hay I, Yokomizo A, Liu W, Goellner J, Grant C,
Smith D, Eberhardt N. FHIT and TSG101 in thyroid tumours: aberrant
transcripts reflect rare abnormal RNA processing events of uncertain
pathogenetic or clinical significance. Clin Endocrinol. 2000; 52:749-757
Meireles A, Preto A, Rocha A, Rebocho A, Máximo V, Pereira- Castro I, Moreira
S, Feijão T, Botelho T, Marques R, Trovisco V, Cirnes L, Alves C, Velho
S, Soares P,1,2 Sobrinho-Simões M. Molecular and genotypic
41